Evidence map›Paper›PMID 34803417›Full record

ArticleJournal of blood medicine2021

Outcomes of Patients Who Undergo Transfusion of Fresh Frozen Plasma: A Prospective, Observational, Multicentre Cohort Study in Hiroshima, Japan.

Aya Sugiyama, Teruhisa Fujii, Yoshiko Okikawa, Fumie Sasaki, Masazumi Okajima, Hidekuni Hidaka, Koji Iwato, Kazuyoshi Sato, Akira Kokubunji, Noboru Takata and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of blood medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Aya SugiyamaDepartment of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Teruhisa FujiiDivision of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Yoshiko OkikawaDepartment of Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Fumie SasakiDivision of Laboratory, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Masazumi OkajimaJoint Committee for Blood Transfusion Therapy in Hiroshima Prefecture, Hiroshima, Japan.
Hidekuni HidakaJoint Committee for Blood Transfusion Therapy in Hiroshima Prefecture, Hiroshima, Japan.
Koji IwatoJoint Committee for Blood Transfusion Therapy in Hiroshima Prefecture, Hiroshima, Japan.
Kazuyoshi SatoJoint Committee for Blood Transfusion Therapy in Hiroshima Prefecture, Hiroshima, Japan.
Akira KokubunjiJoint Committee for Blood Transfusion Therapy in Hiroshima Prefecture, Hiroshima, Japan.
Noboru TakataJoint Committee for Blood Transfusion Therapy in Hiroshima Prefecture, Hiroshima, Japan.
Masahiro YamamotoJoint Committee for Blood Transfusion Therapy in Hiroshima Prefecture, Hiroshima, Japan.
Junko TanakaDepartment of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiroshima City Asa Citizens Hospital · JPHiroshima University · JPFukuyama City Hospital · JPHiroshima International University · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPHiroshima University Hospital · JPJapanese Red Cross Hiroshima College of Nursing · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGiven the chronic shortage of blood for transfusion in Japan, promotion of appropriate use of fresh frozen plasma (FFP) urgently needs to be addressed by the national blood project in Japan. Whether FFP transfusions are administered appropriately in Japan is currently unclear. In this study, we aimed to investigate the outcomes of patients who undergo FFP transfusion and the appropriateness of use of FFP. PATIENTS AND

methodsThis multicentre, prospective, observational cohort study was conducted from September 2017 to April 2019 at the 15 medical institutions in Hiroshima Prefecture that are the top providers of FFP. All patients who underwent FFP transfusion during the study period were included, relevant data being extracted from the medical records. The indications for FFP transfusion were classified in accordance with the Guidelines of the Ministry of Health, Labour and Welfare of Japan. Factors associated with patient outcomes at day 28 after FFP transfusion were subjected to multivariable logistic regression analysis.

resultsIn total, data of 1299 patients were eligible for analysis. At least 63.8% of indications for FFP were in accordance with the guideline for FFP transfusions. The mortality rate at day 28 after FFP transfusion was 16.2%. Older age (65-74 years: adjusted odds ratio [AOR]=4.3, ≥75 years: AOR=4.1), non-perioperative use (AOR=4.5), coagulopathy associated with liver damage (AOR=2.7), large volume of FFP transfused (AOR=2.5), and lack of improvement in blood coagulation following FFP transfusion were independently and significantly associated with death within 28 days after FFP transfusion.

conclusionOur findings do not support the simple conclusion that FFP transfusions contribute to prognosis. However, given that coagulopathy in patients with end-stage liver disease is infrequently improved by FFP transfusion, "inappropriate" use of FFP should be avoided. It is important to promote appropriate use of FFP so as not to waste blood resources.

Indexed as

coagulopathycompliance with guidelineinappropriate useprognosis

Identifiers

PMID34803417
PMCPMC8594890
OpenAlexW3211408501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.